Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians

  • Nix D
  • Majumdar A
  • DiNubile M
  • 49

    Readers

    Mendeley users who have this article in their library.
  • 80

    Citations

    Citations of this article.

Abstract

Ertapenem, a Group 1 carbapenem, is a once-a-day parenteral beta-lactam antibiotic recently licensed in the USA and Europe. Monotherapy with ertapenem dosed as 1 g once a day has been shown to be highly effective in clinical trials for the treatment of complicated infections of skin and skin structures, complicated intra-abdominal infections, community-acquired pneumonia, acute pelvic infections and complicated urinary tract infections. Dosing modifications have not been recommended for adults on the basis of gender, age, weight or liver disease. Presently there are no data regarding the use of ertapenem in children. Dose reductions are indicated for patients with advanced renal insufficiency. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected.

Author-supplied keywords

  • Carbapenems
  • Distribution
  • Excretion
  • Metabolism
  • Protein binding
  • Renal insufficiency

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • David E. Nix

  • Anup K. Majumdar

  • Mark J. DiNubile

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free